Get the Stockscreener App
0.3639
20.46%
0.0618
After Hours:
.37
0.0061
+1.68%
Ernexa Therapeutics Inc stock is traded at $0.3639, with a volume of 1.68M.
It is up +20.46% in the last 24 hours and down -72.01% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$0.3021
Open:
$0.3075
24h Volume:
1.68M
Relative Volume:
6.73
Market Cap:
$2.86M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0438
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
-46.49%
1M Performance:
-72.01%
6M Performance:
-78.47%
1Y Performance:
-90.74%
1-Day Range:
$0.2916
$0.3783
1-Week Range:
$0.2682
$0.4183
52-Week Range:
$0.2682
$5.547
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.3639 | 2.37M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
What hedge fund activity signals for Ernexa Therapeutics Inc. stockJuly 2025 PostEarnings & Target Return Focused Picks - mfd.ru
Ernexa Therapeutics prices $10.5 million public offering at $0.50 per share - Investing.com
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - The Manila Times
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Street Watch: Is Ernexa Therapeutics Inc forming bullish engulfing patternsQuarterly Investment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Valuation Update: Why is Ernexa Therapeutics Inc stock going up2025 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA - Quiver Quantitative
Ernexa Therapeutics Participates in Virtual Investor “What - GlobeNewswire
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Yahoo Finance
Japanese trade program selects Ernexa Therapeutics among elite biotech group - Investing.com Canada
Ernexa Therapeutics Selected for Japan Entry Acceleration Program to Advance Innovative Cell Therapies - Quiver Quantitative
Ernexa Therapeutics Selected as One of Only Ten Global - GlobeNewswire
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - The Globe and Mail
New Highs: Can Ernexa Therapeutics Inc be recession proofEarnings Overview Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Ernexa Therapeutics Inc. be recession proofJuly 2025 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
Breakout Zone: Is RICK showing insider buyingRisk Management & Growth Focused Investment Plans - baoquankhu1.vn
Update Report: Is Ernexa Therapeutics Inc forming bullish engulfing patternsEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Can Ernexa Therapeutics Inc continue delivering strong returnsPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Volume Report: What is TTGTs revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review - Defense World
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Aug PostEarnings: Will Ernexa Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Top Performers Watchlists - Bộ Nội Vụ
Bull Run: How institutional buying supports Ernexa Therapeutics Inc stockJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Is Ernexa Therapeutics Inc. stock trading at a premium valuationJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
How Ernexa Therapeutics Inc. stock reacts to inflationary pressures2025 Price Momentum & Daily Price Action Insights - Улправда
How Ernexa Therapeutics Inc. stock compares to industry benchmarksCPI Data & Low Risk High Win Rate Picks - ulpravda.ru
Ernexa’s stem cell therapy could soon enter ovarian cancer trials - Rare Cancer News
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Ernexa Therapeutics announces successful pre-Ind FDA meeting - marketscreener.com
Ernexa receives FDA alignment for ovarian cancer cell therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Advances Ovarian Cancer Treatment Toward First-in-Human Trial After FDA Meeting - Quiver Quantitative
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-In-Human Trial in Ovarian Cancer - marketscreener.com
Will Ernexa Therapeutics Inc. stock pay special dividends2026 world cup usa national team group stage key players possession football group prediction preview - Улправда
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Published on: 2026-01-02 17:34:55 - Bộ Nội Vụ
How Low Can Ernexa Therapeutics Stock Really Go? - Trefis
Is Ernexa Therapeutics Inc. stock attractive for growth ETFsEarnings Growth Report & Technical Confirmation Trade Alerts - DonanımHaber
How Ernexa Therapeutics Inc. stock performs in rate cut cyclesQuarterly Earnings Report & Expert Curated Trade Setups - DonanımHaber
Ernexa Therapeutics (NASDAQ:ERNA) Stock Price Down 5.1% – Here’s What Happened - Defense World
Ernexa Therapeutics Earnings Notes - Trefis
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Ernexa Therapeutics stock falls after ASH meeting presentation By Investing.com - Investing.com Australia
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Ernexa reports promising preclinical data for cancer cell therapy By Investing.com - Investing.com Australia
Ernexa Therapeutics Presents New Preclinical Data on ERNA-101 at ASH Annual Meeting Highlighting Innovative Cell Therapy Potential to Combat Cancer - Quiver Quantitative
Ernexa reports promising preclinical data for cancer cell therapy - Investing.com
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):